(NYSEMKT: PLX) Protalix Biotherapeutics's forecast annual revenue growth rate of 4.68% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 281.91%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.58%.
Protalix Biotherapeutics's revenue in 2025 is $61,840,000.On average, 3 Wall Street analysts forecast PLX's revenue for 2025 to be $4,908,104,676, with the lowest PLX revenue forecast at $4,640,623,828, and the highest PLX revenue forecast at $5,232,764,984. On average, 3 Wall Street analysts forecast PLX's revenue for 2026 to be $5,725,264,297, with the lowest PLX revenue forecast at $4,870,547,985, and the highest PLX revenue forecast at $6,685,573,619.
In 2027, PLX is forecast to generate $5,647,577,436 in revenue, with the lowest revenue forecast at $5,479,818,852 and the highest revenue forecast at $5,871,309,161.